Cleveland, Ohio — February 16, 2026 — Celloram Inc., a U.S.-based clinical-stage biotechnology company focused on developing innovative therapies for cancer and immune-mediated diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent application covering a novel class of small-molecule inhibitors of fatty acid binding proteins (FABPs), including their pharmaceutically acceptable salts, methods of use, and methods of manufacture.
The allowed claims provide strong composition-of-matter protection for a novel family of FABP inhibitor compounds, including specific example molecules, their salts, and related chemical variants, significantly strengthening the intellectual property position of the program.
The disclosed inventions relate to FABP inhibitor compounds and their use in pharmaceutical compositions for the treatment of diseases characterized by elevated FABP expression. These include hard-to-treat metastatic cancers, as well as inflammatory, autoimmune, and metabolic disorders. The patent also includes methods for preparing the disclosed compounds, supporting downstream development and manufacturing activities.
Fatty acid binding proteins (FABPs) play a key role in cellular lipid transport and energy metabolism. In pathological states, diseased cells often exhibit increased energy demands and rely heavily on fatty acid utilization; FABP inhibitors are designed to disrupt this metabolic dependency, thereby reducing pathological cell activity and helping to alleviate disease symptoms.
“This allowance represents an important milestone for Celloram’s intellectual property portfolio,” said Tej Pareek, Ph.D., CEO of Celloram Inc. “Strong composition-of-matter protection around our FABP inhibitor program provides a critical foundation for continued translational development, value creation, and potential strategic partnerships.”
Dr. John Letterio, M.D., Co-Founder of Celloram, added, “Targeting metabolic dependencies in cancer and immune-mediated diseases represents a powerful and emerging therapeutic strategy. Securing strong composition-of-matter protection at this stage provides critical momentum as we translate this science toward meaningful clinical impact for patients with limited treatment options.”
Dr. Seong Jin Kim, Ph.D., Co-Founder of Celloram, and MedPacto CEO said, “Celloram’s FABP inhibitor platform is built on years of mechanistic research into lipid metabolism and disease biology. This patent allowance validates the novelty of our chemistry and strengthens the foundation for advancing these compounds into clinical development and global partnerships.”
Upon issuance, the patent is expected to provide robust exclusivity in the United States, supporting Celloram’s ongoing preclinical and clinical development efforts and reinforcing the company’s broader strategy of building a defensible global intellectual property estate around differentiated therapeutic platforms.
About Celloram Inc.
Celloram Inc. is a Cleveland-based biotechnology company developing first-in-class and best-in-class therapies for cancer and immune-mediated diseases. The company integrates mechanistic biology, medicinal chemistry, and translational science to advance proprietary therapeutic assets toward clinical development.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding intellectual property protection, development plans, and potential business opportunities. These statements are subject to risks and uncertainties that could cause actual results to differ materially. No assurance can be given that any patent will provide specific commercial advantages or that development programs will proceed as anticipated.
